SG Americas Securities LLC Invests $100,000 in Janux Therapeutics, Inc. (NASDAQ:JANX)

SG Americas Securities LLC bought a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 9,345 shares of the company’s stock, valued at approximately $100,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of Janux Therapeutics by 34.9% in the 1st quarter. JPMorgan Chase & Co. now owns 17,926 shares of the company’s stock valued at $256,000 after purchasing an additional 4,638 shares during the period. Bank of New York Mellon Corp lifted its position in Janux Therapeutics by 25.9% during the 1st quarter. Bank of New York Mellon Corp now owns 46,001 shares of the company’s stock valued at $660,000 after acquiring an additional 9,464 shares during the period. MetLife Investment Management LLC boosted its stake in Janux Therapeutics by 100.2% during the first quarter. MetLife Investment Management LLC now owns 10,614 shares of the company’s stock worth $152,000 after acquiring an additional 5,312 shares in the last quarter. Rhumbline Advisers grew its holdings in Janux Therapeutics by 46.9% in the first quarter. Rhumbline Advisers now owns 16,216 shares of the company’s stock worth $233,000 after purchasing an additional 5,179 shares during the period. Finally, BlackRock Inc. increased its stake in shares of Janux Therapeutics by 15.2% during the first quarter. BlackRock Inc. now owns 1,161,721 shares of the company’s stock valued at $16,659,000 after purchasing an additional 153,460 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

NASDAQ JANX opened at $48.69 on Friday. Janux Therapeutics, Inc. has a 1-year low of $5.65 and a 1-year high of $58.69. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -36.34 and a beta of 4.18. The business’s fifty day moving average price is $35.20 and its 200-day moving average price is $18.16.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. The business had revenue of $2.46 million during the quarter, compared to the consensus estimate of $0.98 million. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.41 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. BTIG Research began coverage on Janux Therapeutics in a research note on Thursday, March 21st. They issued a “buy” rating and a $62.00 target price on the stock. Cantor Fitzgerald started coverage on shares of Janux Therapeutics in a research note on Wednesday, March 20th. They set an “overweight” rating and a $100.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $53.00 target price on shares of Janux Therapeutics in a research note on Monday, March 11th. Bank of America increased their price target on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, March 13th. Finally, Jonestrading assumed coverage on Janux Therapeutics in a research report on Tuesday, April 16th. They issued a “buy” rating and a $70.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $61.33.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.